A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
Launched by ABBVIE · Dec 18, 2018
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants with diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive
- • Participants must be judged by the investigator to be inadequately controlled by current therapy, have recognizable/identifiable "Off" and "On" states (motor fluctuations), and have a minimum of 2.5 hours of "Off" time per day
- Exclusion Criteria:
- • Participant is cognitively impaired and is not able to safely and effectively manage the drug delivery system and the diaries and is not able to adhere to the study
- • Participant is considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Sun City, Arizona, United States
Fountain Valley, California, United States
Aurora, Colorado, United States
Boca Raton, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Kansas City, Kansas, United States
Lexington, Kentucky, United States
Boston, Massachusetts, United States
Saint Paul, Minnesota, United States
Columbia, Missouri, United States
Saint Louis, Missouri, United States
Lebanon, New Hampshire, United States
Raleigh, North Carolina, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Dallas, Texas, United States
Houston, Texas, United States
Round Rock, Texas, United States
San Antonio, Texas, United States
Kirkland, Washington, United States
Spokane, Washington, United States
Milwaukee, Wisconsin, United States
Concord, New South Wales, Australia
Westmead, New South Wales, Australia
Adelaide, South Australia, Australia
Melbourne, Victoria, Australia
Nedlands, Western Australia, Australia
Leuven, Vlaams Brabant, Belgium
Brugge, , Belgium
Liege, , Belgium
Calgary, Alberta, Canada
Quebec City, Quebec, Canada
Copenhagen Nv, Hovedstaden, Denmark
Aarhus N, Midtjylland, Denmark
Odense C, Syddanmark, Denmark
Ulm, Baden Wuerttemberg, Germany
Beelitz Heilstaetten, , Germany
Haag, , Germany
Messina, , Italy
Milan, , Italy
Padova, , Italy
Asahikawa Shi, Hokkaido, Japan
Kyoto Shi, Kyoto, Japan
Suita Shi, Osaka, Japan
Bunkyo Ku, Tokyo, Japan
Kodaira Shi, Tokyo, Japan
Rotterdam, Zuid Holland, Netherlands
Nieuwegein, , Netherlands
Sestroretsk, Sankt Peterburg, Russian Federation
St. Petersburg, Sankt Peterburg, Russian Federation
Elche, Alicante, Spain
L'hospitalet De Llobregat, Barcelona, Spain
A Coruna, , Spain
Barcelona, , Spain
Granada, , Spain
Madrid, , Spain
Sevilla, , Spain
Lund, Skane Lan, Sweden
Stockholm, Stockholms Lan, Sweden
Gothenburg, Vastra Gotalands Lan, Sweden
Dundee, Scotland, United Kingdom
London, , United Kingdom
Plymouth, , United Kingdom
Portland, Oregon, United States
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials